Gilead Sciences Inc

Type: Company
Name: Gilead Sciences Inc
First reported Jul 25 2014 - Updated 6 hours ago - 3 reports

Gilead's $1,000-a-pill hepatitis C drug breaks records, drives Q2 profit

With record-breaking revenue from its controversial hepatitis C drug, Gilead Sciences Inc. scored a second-quarter profit of nearly $3... ... [Published Nations Restaurant News - 6 hours ago]
First reported Jul 24 2014 - Updated 8 hours ago - 7 reports

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chroni...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion ... [Published BioMedReports - 15 hours ago]
First reported 16 hours ago - Updated 8 hours ago - 9 reports

Europe backs new leukemia drugs from J&J, Gilead

By Reuters StaffLONDON (Reuters) - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.The European Medicines Agency said ... [Published MedCity News - 8 hours ago]
First reported Jul 24 2014 - Updated 12 hours ago - 3 reports

Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside

If your browser does not automatically forward you to http://business-news.thestreet.com/philly/story/jim-cramers-mad-dash-gilead-sciences-still-has-upside/12759898, please click here. ... [Published Philly.com - Jul 24 2014]
First reported Jul 24 2014 - Updated 14 hours ago - 3 reports

Breakthrough: Tablets Preventing HIV Virus Transmission Discovered

A new tablet Truvada, made by Pharmaceutical Company Gilead Sciences, can prevent HIV virus transmission, according to a study published in Lancet, a medical journal.The participants in 2014's International AIDSReutersTablet Truvada (a combination of ... [Published International Business Times Australia - 14 hours ago]
First reported Jul 24 2014 - Updated 15 hours ago - 2 reports

Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger

Gilead Sciences ( NASDAQ: GILD     ) is finally an oncology company. It's been years in the making .On Wednesday, the biotech got Zydelig approved to treat three different B-cell blood cancers: chronic lymphocytic leukemia, follicular B-cell non-Hodgkin ... [Published Motley Fool Discussion Boards - 15 hours ago]
First reported Jul 24 2014 - Updated Jul 25 2014 - 11 reports

Investors Commend Gilead Sciences for Increasing Access to Life-Saving HIV/AIDS Drug Via Medicines Patent Pool

Company’s licensing agreement with MPP for generic production of tenofovir alafenamide shows leadership and innovation in delivering HIV/AIDS medicines where they are most needed.New York, NY, Thursday, July 24, 2014 – Members of the Interfaith Center ... [Published Interfaith Center on Corporate Responsibility - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 31 reports

A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval

By DoctoRx:Gilead Sciences (NASDAQ: GILD ) reported yet another record quarter Wednesday after the bell, of $2.36 per share, which compares with $1.48 in Q1 and much lower in Q2 2013 (all data non-GAAP). Sales of Sovaldi for hepatitis C reached $3.5 B, ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 7 reports

Gilead: Even This Raging Bull Was Too Pessimistic

By Bret Jensen :Wow!! This author rarely engages in hyperbole, but it is hard to come up with another word that accurately describes the results biotech Gilead Sciences (NASDAQ: GILD ) reported after the bell yesterday. This comes from a raging bull ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 4 reports

Can Gilead break into cancer? With Zydelig approval, it gets its chance

Gilead Sciences ($GILD) knows how to sell antiviral drugs. Its multibillion-dollar HIV business boasts some of the biggest launches in recent history. And its newly minted hepatitis C drug Sovaldi? The wildly successful treatment is expected to hit $10 ... [Published FiercePharma - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 3 reports

Update: Gilead Sciences Earnings

Summary Q2 2014 EPS reported of $2.36 per share is up 372% Y/Y. Q2 earnings have confirmed my earlier opinion of the stock. For the full year, Gilead updated guidance from sales of about $11.4 billion to about $22 billion.Gilead Sciences (NASDAQ: GILD ... [Published Seeking Alpha - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 6 reports

Gilead pill reaches $3.48B in quarterly sales

Despite criticism from insurers and lawmakers, Gilead Sciences said Wednesday its $1,000-a-day hepatitis C pill had improved on its record-setting debut as it reached $3.48 billion in sales last quarter.The drug, Sovaldi, can cure more than 90 percent ... [Published San Francisco Chronicle - Jul 24 2014]

Quotes

Kristin Comella, Bioheart's Chief Scientific Officer, attended the case and said, "We are bringing new regenerative therapies to many patients around the world. We believe that this new method of cell combination is the best therapy available to patients suffering from heart failure."
...The agency said both drugs "have the potential to bring new treatment options for patients suffering from these rare cancers, especially in cases where previous treatments have stopped working, as they act in different ways to previously authorised medicines."
On top of those threats, Novartis " Sandoz is already developing a biosimilar generic version of Humira it hopes to launch once Humira's patent expires. If Novartis is successful, Humira's sales will likely fall more quickly after it loses exclusivity."
"It's really hard to do this upfront payment for a return that may never come and will certainly come many years later" Salo said

More Content

All (1792) | News (1293) | Reports (0) | Blogs (456) | Audio/Video (0) | Fact Sheets (7) | Press Releases (27)
sort by: Date | Relevance
Town Hall Forum to Address Hepatitis C [Published Afro American Newspaper - 2 hours ago]
The Drug That’s Forcing America’s Most Importan... [Published BioPortfolio - 3 hours ago]
Bioheart Announces World's First Combination St... [Published BioMedReports - 4 hours ago]
Politicizing Gilead's Research And Development ... [Published Forbes.com - 5 hours ago]
Gilead's $1,000-a-pill hepatitis C drug breaks ... [Published Nations Restaurant News - 6 hours ago]
Does your portfolio need medical attention? Try... [Published Business News Network - 6 hours ago]
States limit Medicaid users’ access to costly h... [Published Walla Walla Union-Bulletin - 7 hours ago]
EMA committee backs Johnson & Johnson's Imbruvi... [Published FirstWord Pharma - 7 hours ago]
Europe backs new leukemia drugs from J&J, Gilead [Published MedCity News - 8 hours ago]
Gilead anticipates expansion of HBV, HIV drug i... [Published Orthopedics Today - 8 hours ago]
Why Janet Yellen is wrong about biotech and soc... [Published Globe and Mail - 8 hours ago]
New Hepatitis C Treatment: $84K Per Three-Month... [Published Crooks and Liars - 8 hours ago]
Humira Still Key to AbbVie [Published Motley Fool Discussion Boards - 8 hours ago]
New licensing agreement could improve treatment... [Published Infrosoft - 8 hours ago]
Blood Cancer Drug Gets Positive CHMP Opinion [Published BioPortfolio - 8 hours ago]
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed... [Published JD Supra - 9 hours ago]
Europe backs new leukemia drugs from J&J and Gi... [Published DailyMe.Com - 9 hours ago]
Cancer medicines get regulatory nod [Published MedNous - 10 hours ago]
World: At AIDS Conference, Prevention Pill Stir... [Published ReliefWeb - Latest Updates - 10 hours ago]
Why Sovaldi took off: Previous treatments were ... [Published Ezra Klein - 11 hours ago]
International Activists Confront Gilead Over He... [Published The Body - 11 hours ago]
Company Update: Gilead Sciences Inc (NASDAQ:GIL... [Published Jutia Group - 12 hours ago]
New licensing agreement could improve treatment... [Published EurekAlert! - 12 hours ago]
Uptrend Call Working As Gilead Sciences Stock R... [Published Individual.com - 13 hours ago]
AbbVie Profit Beats Analyst Estimates on Higher... [Published Washington Post - 13 hours ago]
Company Update: Gilead Sciences Inc (NASDAQ:GIL... [Published Pettinga Financial Advisors - 13 hours ago]
Viewpoints: Ryan's 'Thoughtful Blueprint' To En... [Published Kaiser Health News - 13 hours ago]
WaterFire lights flame for those affected by Hep C [Published WPRI - 13 hours ago]
European Medicines Agency recommends approval o... [Published FiercePharma - 14 hours ago]
Breakthrough: Tablets Preventing HIV Virus Tran... [Published International Business Times Australia - 14 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
New Hepatitis C Treatment: $84K Per Three-Month... [Published Crooks and Liars - 8 hours ago]
Since the federal government already provides so much of the R&D funding for pharmaceutical companies, and Big Pharma really exploits its stranglehold on certain drugs, maybe it's time to talk about either federal price ceilings, partial ownership ...
World: At AIDS Conference, Prevention Pill Stir... [Published ReliefWeb - Latest Updates - 10 hours ago]
Source: Voice of AmericaCountry: World MELBOURNE, AUSTRALIA — Participants in this year’s International AIDS Conference welcomed progress on a new pill that may prevent transmission of the deadly HIV virus – one of the advances that have provoked celebrations ...
Why Sovaldi took off: Previous treatments were ... [Published Ezra Klein - 11 hours ago]
  Gilead Sciences president and chief operating officer John Milligan (Victor J. Blue/Bloomberg) In a  story  Thursday, I dove into the societal implications of the new $84,000 hepatitis C treatment. There's one part I want to expand upon further: ...
Gilead Sciences (GILD) Showing Bullish Technica... [Published MarketIntelligenceCenter.com - 15 hours ago]
The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Gilead Sciences Inc (GILD) that should provide a 5.73% return in just 57 days. Sell one Sep. '14 call at the $92.50 level for each 100 ...
European CHMP Adopts Positive Opinion for Gilea... [Published Business Wire Health News - 16 hours ago]
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
The Zacks Analyst Blog Highlights:AbbVie, Shire... [Published Financial Services - Jul 17 2014]
Critical Alerts For SunEdison, Twitter, Gilead ... [Published Financial Services - Jul 14 2014]
NDA Submission, Results Release Schedules, FDA ... [Published Financial Services - Jul 04 2014]
Biotechnology Equities Technical Notes -- Resea... [Published Financial Services - Jun 26 2014]
Critical Alerts For Ralph Lauren, Rackspace Hos... [Published Financial Services - Jun 13 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.